AlphaRx Appoints Advisory Board Member.Business Editors, Health & Medical Writers BIOWIRE2K RICHMOND HILL, Ontario--(BW HealthWire)--Feb. 28, 2001 AlphaRx Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AHRX) is pleased to announce the appointment of Peter Carlen, MD, FRCP FRCP Fellow of the Royal College of Physicians. FRCP abbr. Fellow of the Royal College of Physicians (C) to the Company's Advisory Board. Dr. Carlen is Professor of Medicine (Neurology) and Physiology at the University of Toronto Research at the University of Toronto has been responsible for the world's first electronic heart pacemaker, artificial larynx, single-lung transplant, nerve transplant, artificial pancreas, chemical laser, G-suit, the first practical electron microscope, the first cloning of T-cells, , and a clinical Neurologist/scientist at the Playfair Neuroscience Research Unit at the Toronto Hospital Research Institute, University of Toronto. Dr. Carlen has published over 175 peer-reviewed articles in the fields of Neurology and drug and alcohol addiction and has lectured throughout the world on these subjects. "We are pleased and fortunate to have Dr. Carlen as a member of our Advisory Board," said Mr. Michael Lee, President of AlphaRx. "He will be involved in pre-clinical and clinical studies of our BCD (Binary Coded Decimal) The storage of numbers in which each decimal digit is converted into binary and is stored in a single character or byte. For example, a 12-digit number would take 12 bytes. See binary numbers. drug delivery system, as applied to neuroprotective drugs. Part of this research will involve investigations into the neuroprotective anti-inflammatory activity of our newly discovered immunomodulating compounds, code named ARX-2001 and ARX-2002." "Immunomodulators" are synthetic or natural source drugs, used to treat certain medical conditions through their selective immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. stimulation or suppression. Stimulation is important, for example, in the body's defence against cancer by activating tumor-killing cells, and in enhancing the defence against pathogens such a viruses and bacteria in surgery and burn patients and individuals with compromised immune system diseases such as AIDS. Suppression is important in treating conditions caused by an overactive o·ver·ac·tive adj. Active to an excessive or abnormal degree: an overactive child. o immune response, such as arthritis. Currently available immunomodulators such as interferons, cytokines Cytokines Chemicals made by the cells that act on other cells to stimulate or inhibit their function. Cytokines that stimulate growth are called "growth factors. , polypeptides and tissue extracts show inconsistent results, serious side-effects and are expensive. In preliminary investigations, AlphaRx's newly discovered ARX-2000 "series" compounds have shown significant immune system modulating properties, low toxicity, fast onset and prominent anti-inflammatory activity, overcoming many of these deficiencies. Successfully developed, they offer great potential for the future of immunomodulation therapy, suitable for the treatment of immune deficiency states including cancer, AIDS, Alzheimer's disease, multiple sclerosis and severe acute and chronic inflammatory conditions such as arthritis and colitis. FORWARD LOOKING STATEMENTS: This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion